Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the rationale for using PARP inhibitors in combination with other therapies for prostate cancer.
Karim Fizazi, MD, PhD
Joaquin Mateo, MD, PhD
Released: April 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

  • Possible synergy between PARP inhibitors and androgen receptor–directed therapy
  • Rationale for PARP inhibitors and immunotherapy combinations
  • Benefits and challenges of combining DNA damaging agents and PARP inhibitor

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Related Content

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Downloadable short slideset from CCO on current treatment recommendations and adverse event management strategies for patients with advanced RCC.

Neeraj Agarwal, MD Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue